Revolution Medicines启动RMC-5127临床试验 首位患者完成给药

美股速递
Jan 29

Revolution Medicines, Inc. (简称:Revolution Medicines) 宣布,其针对RAS(ON) G12V选择性抑制剂RMC-5127的临床试验已正式启动,首位患者成功完成给药。该抑制剂旨在精准靶向特定的RAS基因突变,为相关癌症治疗提供新的潜在方案。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10